Skip to main content
. Author manuscript; available in PMC: 2015 Sep 24.
Published in final edited form as: Radiat Res. 2015 Aug 18;184(3):235–248. doi: 10.1667/RR14186.1

FIG. 2.

FIG. 2

Illustration of how different entities: academia, various components of the DHHS (Radiation Research Program); SBIR Development Center; the NIAID’s Medical Countermeasure Development Program and BARDA; the small business research community; and the pharmaceutical industry, serve different niches along the development pathways in research and development and the concept of potential synergy in investment to facilitate the commercialization of radioprotectors and radiomitigators.